AGIOS PHARMACEUTICALS, INC.

Listed Company

AGIOCIK 0001439222NasdaqLarge AcceleratedPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$54.03M

Net Income

$-412.78M

Total Assets

$1.30B

Equity

$1.19B

Shares Out

59.47M

Op. Cash Flow

$-372.98M

AGIO$39.60−1.97% · past yearDBEQ Basic

Daily closing prices

Business

Agios Pharmaceuticals is a commercial-stage biopharmaceutical company developing innovative medicines for rare diseases, particularly hemolytic anemias and other rare hematological disorders. The company's lead product, mitapivat (PYRUKYND®/AQVESME™), a pyruvate kinase activator, is FDA-approved for pyruvate kinase deficiency and thalassemia, with additional indications in development. Agios operates in classical hematology and cellular metabolism, advancing a pipeline including tebapivat for lower-risk myelodysplastic syndromes and sickle cell disease, AG-181 for phenylketonuria, and AG-236 for polycythemia vera. The company commercializes directly in the United States and through distribution partners in Europe and the Middle East.

Summary from 10-K filed 2026-02-12

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total product revenue, net	54	36	27	14	0
Cost of sales	6	4	3	2	0
Research and development	340	301	296	280	257
Total selling, general and administrative expenses	180	157	120	122	121
Total operating expenses	526	462	418	403	378
Loss from operations	−472	−426	−391	−389	−378
Gain on sale of contingent payments	0	889	0	128	0
Milestone payment from gain on sale of oncology business	0	200	0	0	7
Interest income, net	56	48	33	13	836,000
Other income, net	2	6	6	7	14
Net (loss) income before taxes	−414	718	−352	−232	−357
Income tax (benefit) expense	−1	44	0	0	—
Net (loss) income	−413	674	−352	−232	1,605
Net income (loss) per share - basic (in usd per share)	−7.12	11.86	−6.33	−4.23	26.55
Net income (loss) per share - diluted (in usd share)	−7.12	11.64	−6.33	−4.23	26.55
Weighted-average number of common shares used in computing net income (loss) per share basic (in shares)	58	57	56	55	60
Weighted-average number of common shares used in computing net income (loss) per share diluted (in shares)	58	58	56	55	60

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	89	76	88	139	203
Marketable securities	765	817	689	644	817
Accounts receivable, net	11	4	3	2	0
Inventory	33	28	19	8	0
Prepaid expenses and other current assets	44	40	35	39	40
Total current assets	942	966	834	833	1,064
Marketable securities	310	638	29	314	266
Operating lease assets	30	43	54	65	75
Property and equipment, net	11	12	15	23	29
Other non-current assets	4	5	4	4	3
Total assets	1,297	1,663	937	1,239	1,438
Accounts payable	18	17	10	19	17
Accrued expenses	45	47	43	30	32
Income taxes payable	0	871,000	0	—	—
Operating lease liabilities	18	17	15	14	11
Total current liabilities	82	81	68	63	60
Operating lease liabilities, net of current portion	22	40	57	72	86
Other non-current liabilities	90,000	880,000	1	3	0
Total liabilities	104	122	126	138	146
Commitments and contingent liabilities (Note 14)	—	—	—	—	—
Preferred stock, $0.001 par value; 25,000,000 shares authorized, no shares issued and outstanding at December 31, 2025 and 2024	0	0	0	0	0
Common stock, $0.001 par value; 125,000,000 shares authorized; 74,665,003 shares issued and 58,448,592 outstanding at December 31, 2025 and 73,372,696 shares issued and 57,156,285 outstanding at December 31, 2024	75,000	73,000	72,000	71,000	71,000
Additional paid-in capital	2,555	2,494	2,437	2,386	2,334
Accumulated other comprehensive income (loss)	2	−2	−441,000	−13	−1
Accumulated deficit	−562	−149	−823	−471	−239
Treasury stock, at cost (16,216,411 shares at December 31, 2025 and December 31, 2024)	−802	−802	−802	−802	−802
Total stockholders equity	1,193	1,541	811	1,101	1,292
Total liabilities and stockholders equity	1,297	1,663	937	1,239	1,438

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	5	6	7	9	9
Stock-based compensation expense	53	43	45	49	54
Net accretion of discount on marketable securities	−7	−14	−5	−1	7
Loss (gain) on disposal of property and equipment	5,000	−39,000	553,000	−48,000	12,000
Non-cash operating lease expense	12	12	11	10	10
Expense associated with license agreement	10	0	18	0	0
Realized gain on investments	−118,000	−167,000	−28,000	—	—
Accounts receivable, net	−6	−1	−604,000	−2	0
Inventory	−5	−9	−11	−8	0
Prepaid expenses and other current and non-current assets	−3	−6	4	−176,000	−27
Accounts payable	2	7	−9	3	2
Accrued expenses	−1	4	13	−2	66,000
Income taxes payable	−871,000	871,000	0	0	—
Operating lease liabilities	−17	−15	−14	−11	−8
Other liabilities	−790,000	−276,000	−2	3	0
Net cash used in operating activities	−373	−390	−296	−309	−407
Purchases of marketable securities	−642	−1,542	−418	−1,031	−1,378
Proceeds from maturities and sales of marketable securities	1,033	818	675	1,146	830
Proceeds from sale of contingent payments	0	889	0	132	0
Proceeds from milestone payment from gain on sale of oncology business	0	200	0	0	—
Payments associated with license agreement	−10	0	−18	0	0
Purchases of property and equipment	−4	−2	−999,000	−5	−6
Proceeds from sale of equipment	0	40,000	1	964,000	0
Net cash provided by investing activities	377	363	240	243	1,249
Net proceeds from stock option exercises and employee stock purchase plan	9	14	5	3	37
Net cash provided by financing activities	9	14	5	2	−766
Net change in cash and cash equivalents	13	−12	−51	−64	76
Additions to property and equipment in accounts payable and accrued expenses	283,000	317,000	55,000	158,000	2
Net cash taxes paid	628,000	43	2	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is AGIOS PHARMACEUTICALS, INC.'s CIK number?

AGIOS PHARMACEUTICALS, INC.'s SEC CIK number is 0001439222 (1439222). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find AGIOS PHARMACEUTICALS, INC.'s SEC filings?

All of AGIOS PHARMACEUTICALS, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did AGIOS PHARMACEUTICALS, INC. last report earnings?

AGIOS PHARMACEUTICALS, INC. (AGIO) most recently filed an earnings 8-K with the SEC on Apr 29, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001439222-26-000071). This is AGIOS PHARMACEUTICALS, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is AGIOS PHARMACEUTICALS, INC.'s most recent earnings 8-K?

AGIOS PHARMACEUTICALS, INC.'s latest earnings 8-K (Item 2.02) was filed Apr 29, 2026 under accession 0001439222-26-000071. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View AGIOS PHARMACEUTICALS, INC.'s latest earnings 8-K →
Look up any company's CIK number →